Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised... by Oliveira, Mafalda, MD PhD, Rugo, Hope S, Prof, Howell, Sacha J, FRCP, Dalenc, Florence, MD PhD, Cortes, Javier, MD PhD, Gomez, Henry L, MD PhD, Hu, Xichun, Prof, Toi, Masakazu, MD, Jhaveri, Komal, MD FACP, Krivorotko, Petr, MD PhD, Loibl, Sibylle, Prof, Morales Murillo, Serafin, MD, Okera, Meena, MD, Nowecki, Zbigniew, MD, Park, Yeon Hee, Prof, Sohn, Joo Hyuk, MD, Tokunaga, Eriko, MD PhD, Yousef, Samih, MD, Zhukova, Lyudmila, MD PhD, Fulford, Marta, PhD, Andrews, Haylee, MPH, Wadsworth, Ian, PhD, D'Cruz, Celina, PhD, Turner, Nicholas C, Prof

Get full text

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA):... by Llombart-Cussac, Antonio, MD, Cortés, Javier, MD, Paré, Laia, PhD, Galván, Patricia, BS, Bermejo, Begoña, MD, Martínez, Noelia, MD, Vidal, Maria, MD, Pernas, Sònia, MD, López, Rafael, MD, Muñoz, Montserrat, MD, Nuciforo, Paolo, MD, Morales, Serafín, MD, Oliveira, Mafalda, MD, de la Peña, Lorena, PhD, Peláez, Alexandra, MD, Prat, Aleix, Dr

Get full text

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a m... by Saura, Cristina, MD, Hlauschek, Dominik, MS, Oliveira, Mafalda, MD, Zardavas, Dimitrios, MD, Jallitsch-Halper, Anita, PhD, de la Peña, Lorena, PhD, Nuciforo, Paolo, MD, Ballestrero, Alberto, MD, Dubsky, Peter, MD, Lombard, Janine M, MD, Vuylsteke, Peter, MD, Castaneda, Carlos A, MD, Colleoni, Marco, MD, Santos Borges, Giuliano, MD, Ciruelos, Eva, MD, Fornier, Monica, MD, Boer, Katalin, MD, Bardia, Aditya, MD, Wilson, Timothy R, PhD, Stout, Thomas J, MD, Hsu, Jerry Y, MD, Shi, Yi, PhD, Piccart, Martine, Prof, Gnant, Michael, Prof, Baselga, José, MD, de Azambuja, Evandro, MD

Get full text

Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-do... by Oliveira, Mafalda, MD, Pominchuk, Denys, PhD, Nowecki, Zbigniew, Prof, Hamilton, Erika, MD, Kulyaba, Yaroslav, MD, Andabekov, Timur, PhD, Hotko, Yevhen, Prof, Melkadze, Tamar, MD, Nemsadze, Gia, Prof, Neven, Patrick, Prof, Vladimirov, Vladimir, MD, Zamagni, Claudio, MD, Denys, Hannelore, MD, Forget, Frédéric, MD, Horvath, Zsolt, MD, Nesterova, Alfiya, MD, Ajimi, Maxine, PhD, Kirova, Bistra, MBChB, Klinowska, Teresa, PhD, Lindemann, Justin P O, MBChB, Lissa, Delphine, PharmD, Mathewson, Alastair, PhD, Morrow, Christopher J, PhD, Traugottova, Zuzana, MD, van Zyl, Ruaan, PhD, Arkania, Ekaterine, MD

Get full text